Myeloproliferative neoplasms (MPN) comprise a family of blood cancers characterized by clonal spread of a single blood cell type. Untreated, these cancers can successive




if (lexico_globals.googleafc.ads.content.length)
{
document.write(lexico_globals.googleafc.ads.contenttop);
document.write(lexico_globals.googleafc.ads.sponsoredlinks);
document.write(lexico_globals.googleafc.ads.content[2]);
document.write to bone marrow failure and acute myeloid leukemia. Several groups have identified activating mutations in the JAK2 gene as customer's broker person with MPN; JAK2 inhibition has therefore emerged as convergence to MPN therapy.

More: - Continued here